Journal of Clinical Oncology, Vol 21, Issue 22
(November), 2003: 4157-4164
© 2003 American Society for Clinical Oncology
Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical Outcome
Richard W. Tsang,
Mary K. Gospodarowicz,
Melania Pintilie,
Woodrow Wells,
David C. Hodgson,
Alexander Sun,
Michael Crump,
Bruce J. Patterson
From the Departments of Radiation Oncology and Biostatistics, Medical Oncology-Hematology, and Pathology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada.
Address reprint requests to Richard Tsang, MD, Department of Radiation Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario M5G 2M9, Canada; e-mail: richard.tsang{at}rmp.uhn.on.ca.
Purpose: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is a distinct lymphoma with unique clinicopathologic features. We report the clinical outcome of stage I and II MALT lymphoma treated with involved field radiation therapy (RT).
Patients and Methods: From 1989 to 2000, 103 patients with stage IE and IIE disease were referred. Their median age was 60 years, with a 2:1 female predominance. Presenting sites were stomach (17 patients), orbital adnexa (31 patients), salivary glands (24 patients), thyroid gland (13 patients), and other sites (18 patients). Ninety-three patients received RT—85 received RT alone, and eight received chemotherapy and RT—with a median dose of 30 Gy. The median follow-up time was 5.1 years.
Results: A complete response (CR) to RT alone was achieved in 84 of 85 patients. Among CR patients, 14 experienced relapse. Relapse sites were mostly contralateral paired-organ or distant MALT locations and, infrequently, lymph nodes. The crude local control rate with RT was 95.3% (81 of 85 patients). No relapses were observed in patients with stomach or thyroid lymphoma, whereas 14 of 63 patients (22%) experienced relapse in the other sites. The overall 5-year survival rate was 98%, and the disease-free survival rate was 77%. Transformed lymphoma was observed in 14% of patients (two of 14) experiencing relapse.
Conclusion: Moderate-dose RT achieved excellent local control in localized MALT lymphomas and had curative potential for three fourths of the patients. Gastric and thyroid MALT lymphomas had better outcome, whereas distant failures were common for other sites. Despite relapse, the disease often maintained an indolent course.
Presented in part at the 44th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 2002.
This article has been cited by other articles:
|
|
|
|
 
P. L. Zinzani, M. Martelli, V. Poletti, U. Vitolo, P. G. Gobbi, T. Chisesi, G. Barosi, A. J.M. Ferreri, M. Marchetti, N. Pimpinelli, et al.
Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
Haematologica,
September 1, 2008;
93(9):
1364 - 1371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Psyrri, S. Papageorgiou, and T. Economopoulos
Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management
Ann. Onc.,
July 22, 2008;
(2008)
mdn525v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al.
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
Ann. Onc.,
May 1, 2008;
19(5):
835 - 846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hatef, D. Roberts, P. McLaughlin, B. Pro, and B. Esmaeli
Prevalence and Nature of Systemic Involvement and Stage at Initial Examination in Patients With Orbital and Ocular Adnexal Lymphoma
Arch Ophthalmol,
December 1, 2007;
125(12):
1663 - 1667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W Fischbach, M E Goebeler, A Ruskone-Fourmestraux, T Wundisch, A Neubauer, M Raderer, A Savio, and for the EGILS (European Gastro-Intestinal Lymphoma
Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series
Gut,
December 1, 2007;
56(12):
1685 - 1687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tanimoto, A. Kaneko, S. Suzuki, N. Sekiguchi, T. Watanabe, Y. Kobayashi, Y. Kagami, A. M. Maeshima, Y. Matsuno, and K. Tobinai
Primary Ocular Adnexal MALT Lymphoma: A Long-term Follow-up Study of 114 Patients
Jpn. J. Clin. Oncol.,
June 11, 2007;
(2007)
hym031v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tsai, S Li, A. Ng, B Silver, M. Stevenson, and P. Mauch
Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma
Ann. Onc.,
April 1, 2007;
18(4):
672 - 678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Decaudin, P. de Cremoux, A. Vincent-Salomon, R. Dendale, and L. L.-L. Rouic
Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options
Blood,
September 1, 2006;
108(5):
1451 - 1460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Raderer, S. Wohrer, B. Streubel, M. Troch, K. Turetschek, U. Jager, C. Skrabs, A. Gaiger, J. Drach, A. Puespoek, et al.
Assessment of Disease Dissemination in Gastric Compared With Extragastric Mucosa-Associated Lymphoid Tissue Lymphoma Using Extensive Staging: A Single-Center Experience
J. Clin. Oncol.,
July 1, 2006;
24(19):
3136 - 3141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M-Q Du and J C Atherton
Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management.
Gut,
June 1, 2006;
55(6):
886 - 893.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Ha, L. J. Medeiros, C. Charnsangavej, M. Crump, and M. K. Gospodarowicz
Oncodiagnosis Panel: 2004: Lymphoma
RadioGraphics,
March 1, 2006;
26(2):
607 - 620.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. von Moos, T. Ruhstaller, and C. Fretz
CASE 3. Red Eye in Sjogren's Syndrome Due to Underlying Mucosa-Associated Lymphoid Tissue Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
1011 - 1013.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tanimoto, A. Kaneko, S. Suzuki, N. Sekiguchi, D. Maruyama, S. W. Kim, T. Watanabe, Y. Kobayashi, Y. Kagami, A. Maeshima, et al.
Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma
Ann. Onc.,
January 1, 2006;
17(1):
135 - 140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Wundisch, C. Thiede, A. Morgner, A. Dempfle, A. Gunther, H. Liu, H. Ye, M.-Q. Du, T. D. Kim, E. Bayerdorffer, et al.
Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter Pylori Eradication
J. Clin. Oncol.,
November 1, 2005;
23(31):
8018 - 8024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bertoni and E. Zucca
State-of-the-Art Therapeutics: Marginal-Zone Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6415 - 6420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Levy, C. Copie-Bergman, C. Gameiro, M.-T. Chaumette, M.-H. Delfau-Larue, C. Haioun, A. Charachon, F. Hemery, P. Gaulard, K. Leroy, et al.
Prognostic Value of Translocation t(11;18) in Tumoral Response of Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue Type to Oral Chemotherapy
J. Clin. Oncol.,
August 1, 2005;
23(22):
5061 - 5066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Pijpe, G W van Imhoff, A Vissink, J E van der Wal, P M Kluin, F K L Spijkervet, C G M Kallenberg, and H Bootsma
Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma
Ann Rheum Dis,
June 1, 2005;
64(6):
958 - 960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Martinelli, D. Laszlo, A. J.M. Ferreri, G. Pruneri, M. Ponzoni, A. Conconi, C. Crosta, E. Pedrinis, F. Bertoni, L. Calabrese, et al.
Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy
J. Clin. Oncol.,
March 20, 2005;
23(9):
1979 - 1983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
